ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on women's reproductive health, announced its participation in the ESHRE Virtual 36th Annual Meeting from July 5-8, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on women's reproductive health, announced its participation in the ESHRE Virtual 36th Annual Meeting from July 5-8, 2020. Dr. Hugh Taylor will present on July 6th about the efficacy and safety of linzagolix for heavy menstrual bleeding related to uterine fibroids. Dr. Oliver Pohl will present on July 7th regarding the action of oxytocin receptor antagonists in assisted reproductive technology. Both presentations will be accessible via ObsEva's website.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -47.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESHRE Virtual 36th Annual Meeting, taking place July 5-8, 2020.
Dr Hugh Taylor, to present on Monday, July 6th, from 11:00 - 11:10 CEST in Session 05
Presentation number: O-190 (pre-selected for Clinical Science Award for Oral Presentation and for the Fertility Society of Australia Exchange Award)
Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial
Dr Oliver Pohl, to present on Tuesday, July 7th, from 15:25 - 15:35 CEST in Session 48
Presentation number: O-027
The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers
The link for both presentations on the ESHRE platform, will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Attachment
- Press Release in Pdf
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.